奧拉帕利對比醫生選擇的化療治療gBRCAm且HER2-轉移性乳腺癌患者
參考文獻:Robson,M E et al.「OlympiAD final overall survival and tolerability results:Olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer.」Annals of oncology:official journal of the European Society for Medical Oncology vol.30,4:558-566.doi:10.1093/annonc/mdz012。